Payment overview · 2025
General Payments
$187.18
11 reported records · 7 companies
Healthcare provider profile · identity verified
Sharon Jamison, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LAWRENCEBURG, KY · NPI 1104815141
Verified facts
What the public records show
CMS Open Payments records show Sharon Jamison, APRN received $187.18 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.78 | 22.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.78 | 16.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.98 | 16.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $25.32 | 13.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.99 | 13.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.29 | 9.2% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $16.04 | 8.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $187.18 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $42.78 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $30.78 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.98 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.98 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $16.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 220 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 204 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 187 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 46 |
| Lisinopril | Lisinopril | 169 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 59 |
| Losartan Potassium | Losartan Potassium | 143 | 41 |
| Potassium Chloride | Potassium Chloride | 116 | 35 |
| Omeprazole | Omeprazole | 115 | 32 |
| Metformin Hcl Er | Metformin Hcl | 112 | 29 |
| Gabapentin | Gabapentin | 111 | 18 |
| Carvedilol | Carvedilol | 105 | 23 |
| Furosemide | Furosemide | 105 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 25 |
| Montelukast Sodium | Montelukast Sodium | 103 | 22 |
| Mounjaro | Tirzepatide | 103 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 32 |
| Eliquis | Apixaban | 96 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 26 |
| Buspirone Hcl | Buspirone Hcl | 81 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 26 |
| Trazodone Hcl | Trazodone Hcl | 76 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 16 |
| Farxiga | Dapagliflozin Propanediol | 67 | 15 |
| Allopurinol | Allopurinol | 64 | 13 |
| Meloxicam | Meloxicam | 60 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 13 |
| Metformin Hcl | Metformin Hcl | 53 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 15 |
| Prednisone | Prednisone | 52 | 35 |
| Sertraline Hcl | Sertraline Hcl | 50 | 14 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Wegovy | Semaglutide | 47 | suppressed |
| Atenolol | Atenolol | 45 | 11 |
| Linzess | Linaclotide | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 12 |
| Januvia | Sitagliptin Phosphate | 43 | 13 |
| Famotidine | Famotidine | 41 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Methocarbamol | Methocarbamol | 39 | 20 |
| Spironolactone | Spironolactone | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 34 |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Simvastatin | Simvastatin | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | 12 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 13 |
| Valacyclovir | Valacyclovir Hcl | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 18 |
| Torsemide | Torsemide | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 12 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 19 | 14 |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Etodolac | Etodolac | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 13 |
| Cefdinir | Cefdinir | 16 | 15 |
| Fluconazole | Fluconazole | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $187.18 · 11 records | ABBVIE INC. | Auvelity, CAPLYTA, FREESTYLE LIBRE 3, INVEGA SUSTENNA, Ozempic, REXULTI, Rybelsus, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error